Mochizuki D Y, Eisenman J R, Conlon P J, Larsen A D, Tushinski R J
Proc Natl Acad Sci U S A. 1987 Aug;84(15):5267-71. doi: 10.1073/pnas.84.15.5267.
A murine in vitro assay was developed to measure potentiation of a proliferative response to suboptimal concentrations of the hematopoietic regulatory molecule granulocyte/macrophage colony-stimulating factor by an immature bone marrow population. The assay, designated the 5-fluorouracil bone marrow proliferation assay, was used to characterize potentiating activity in serum-free culture supernatants of the human tumor cell line HBT 5637. Molecular and biochemical analyses indicated that the HBT 5637-derived potentiating activity could be attributed to interleukin 1 alpha. Serologic analysis using a monoclonal antibody against purified recombinant interleukin 1 alpha proved conclusively that the potentiating activity in HBT 5637 serum-free supernatants is due to interleukin 1 alpha. From these data, the activity of interleukin 1 alpha seems to be the same synergistic activity formerly ascribed to hemopoietin 1.
开发了一种小鼠体外试验,以测量未成熟骨髓群体对造血调节分子粒细胞/巨噬细胞集落刺激因子的亚最佳浓度的增殖反应的增强作用。该试验称为5-氟尿嘧啶骨髓增殖试验,用于表征人肿瘤细胞系HBT 5637无血清培养上清液中的增强活性。分子和生化分析表明,源自HBT 5637的增强活性可归因于白细胞介素1α。使用针对纯化重组白细胞介素1α的单克隆抗体进行的血清学分析确凿地证明,HBT 5637无血清上清液中的增强活性是由于白细胞介素1α。根据这些数据,白细胞介素1α的活性似乎与以前归因于造血素1的协同活性相同。